Literature DB >> 30675324

Diagnosis of Clostridium difficile infection by toxigenic culture and PCR assay.

Elnaze Zare Mirzaei1,2, Mahdi Rajabnia2, Farzin Sadeghi3, Elaheh Ferdosi-Shahandashti2, Mahmoud Sadeghi-Haddad-Zavareh1, Soraya Khafri4, Abolfazl Davoodabadi1,2.   

Abstract

BACKGROUND AND OBJECTIVES: Clostridium difficile is responsible for 15-25% of nosocomial antibiotic associated diarrhea (AAD) cases and all cases of pseudomembranous colitis. C. difficile has two major virulence factors, toxin A (enterotoxin) and toxin B (cytotoxin). The aim of this study was to determine the frequency of C. difficile strains in patients with diarrhea in Babol' hospitals with toxigenic culture and PCR assay.
MATERIALS AND METHODS: One hundred stool specimens were taken from diarrheal patients in hospitals of the city of Babol. All patients had a history of antibiotic use. The samples were cultured on CCFA medium. In the next stage, toxigenic culture was performed for isolated C. difficile strains. Then, PCR assay was used to identify gdh, tcdA and tcdB genes among isolated C. difficile strains.
RESULTS: From the 100 stool samples, eight (8%) samples were positive in C. difficile culture. In toxigenic culture, two (2%) of these strains had cytopathic effects on Vero cells. All eight strains had the gdh gene. This gene is specific for C. difficile. Two strains that had cytopathic effects on toxigenic culture were positive for toxin genes.
CONCLUSION: The frequency of toxigenic strains in different parts of the world is variable, and needs to be continually investigated. In the present study, the PCR method had a good correlation with toxigenic culture. Thus, it can replace the laborious and costly cell culture method.

Entities:  

Keywords:  Antibiotic associated diarrhea; Clostridium difficile; Polymerase chain reaction; Toxigenic culture

Year:  2018        PMID: 30675324      PMCID: PMC6339995     

Source DB:  PubMed          Journal:  Iran J Microbiol        ISSN: 2008-3289


INTRODUCTION

Clostridium difficile is an important cause of nosocomial infections. Symptoms of C. difficile infection (CDI) range from asymptomatic carriage to mild diarrhea, colitis, severe life threatening pseudomembranous colitis and to fulminant colitis (1, 2). This microorganism is responsible for 15–25% of nosocomial antibiotic associated diarrhea (AAD) cases and all cases of pseudomembranous colitis (3, 4). The most predisposing factors for CDI include prior antibiotic therapy, age older than 65 years, and recent long-term hospitalization (5). C. difficile expresses two major virulence factors, which are toxin A (enterotoxin) and toxin B (cytotoxin) encoded via tcdA and tcdB genes respectively (6, 7). There are various tests for diagnosis of CDI in laboratories. Some of these tests are enzyme immunoassay (EIA), glutamate dehydrogenase (GDH), cytotoxicity assay (CA), toxigenic culture and PCR. Enzyme immunoassay is a rapid method and is done directly on stool samples. Although this test is very fast, it has very low sensitivity (8). The GDH test detects glutamate dehydrogenase enzyme in the cell wall of C. difficile. GDH is considered a screening method because it is expressed by both the toxigenic and nontoxigenic strains. GDH is a very rapid, inexpensive and easy method. Unlike toxin A and B tests, this test has high sensitivity but low specificity. However, to confirm positive GDH test results, complementary tests are needed (9). The cell culture cytotoxicity assay (CA), based on toxin B detection is the gold standard for diagnosis of CDI. However, this test is not routinely used by clinical microbiology laboratories, because it requires cell culture facilities and a reliable antitoxin for neutralization (10, 11). The PCR is used to detect toxin A or toxin B genes in strains or directly in fecal samples and in terms of sensitivity is similar to the cytotoxicity assay. In comparison to the cytotoxicity assay, PCR is a very fast method for the diagnosis of CDI (12). To the best of our knowledge, no study to date has examined C. difficile infection in patients with diarrhea in the hospitals of Babol. The aim of the present study was to determine the frequency of C. difficile infection in patients with diarrhea in the hospitals of Babol with toxigenic culture and PCR.

MATERIALS AND METHODS

One hundred stool specimens were taken from diarrheal patients in hospitals of Babol. All patients had a history of antibiotic use, and demographics data of patients were collected via a questionnaire. The specimens were immediately transferred to the microbiology laboratory at Babol University of Medical Sciences. About one gram of stool specimen was suspended in a tube containing one mL of BHI broth (Merck, Germany) and one mL of ethanol 96% (ethanol shock) for 45 min. Then this suspension was cultured on CCFA (cycloserine-cefoxitin fructose agar; Merck, Germany) under anaerobic condition at 37°C for 72 h. The colonies which contained Gram-positive bacilli with 1–3 mm diameter, white to gray color, and horse odour were regarded as C. difficile. The isolated strains were stocked in BHI broth containing 15% glycerol and stored at −20°C.

Toxigenic culture.

In the next stage, toxigenic culture was performed for isolated C. difficile strains. Vero cells were grown in a flask containing Dulbecco’s modified Eagle’s medium (DMEM; Gibco), 100 U/ml penicillin-streptomycin and 10% fetal bovine serum (FBS Gibco), and incubated at 37°C and 5% CO2 for 3–5 days. The cells were trypsinized and counted. About 10,000 cells were added to the wells of microtiterplate and were incubated at 37°C and 5% CO2 for 24 h to reach about 80% confluency. C. difficile strains were cultured in BHI broth for 5–7 days at 37°C, then the culture medium was centrifuged (10 min at 1500 g). The obtaining supernatants were filtered (0.22 μm pore size), and 200 μl of filtrate was added to Vero cell culture (96-well microtiter plate; Biofil, China). The microtiter plate was incubated for 24–48 h at 37°C and 5% CO2. C. difficile strains which produce toxin (positive result), cause cytopathic effects in more than 50% of the cell monolayer. Supernatant obtained from a toxigenic C. difficile strain, which was previously isolated from a diarrheal patient, was used as a positive control in toxigenic culture test (13).

Identification of gdh, tcdA and tcdB genes by PCR assay.

DNA extraction was performed by boiling methods (14). A single colony from every isolate was suspended in 50 ml of TES buffer (containing 50 mM Tris hydrochloride [pH 8.0], 5 mM EDTA, 50 mM NaCl), and the suspension was heated in a boiling water bath at 95°C for 10 min and centrifuged at 15,000 × g for 3 min. The resultant supernatant was used as DNA template. Extracted DNA was stored at −20°C. C. difficile and its toxins were identified by PCR method targeting the gdh (glutamate dehydrogenase), tcdA and tcdB genes. The primers used in this study are listed in Table 1.
Table 1.

Primers used in this study.

GenesPrimer nameSequence (5′–3′)Amplicon size (bp)References
gdhgdh RCTGATTTACACCATTCAGCCATAGC736(15)
gdh FGGAAAAGATGTAAATGTCTTCGAGATG
tcdAtcdA-F3345GCATGATAAGGCAACTTCAGTGGTA629(16)
tcdA-R3969AGTTCCTCCTGCTCCATCAAATG
tcdBtcdB-R6079AGCATTTCTCCATTCTCAGCAAAGTA410(16)
tcdB-F5670CCAAARTGGAGTGTTACAAACAGGTG
Primers used in this study. For each gene, the PCR was run in 20 μL reaction mixture containing 10 μL master mix PCR, 2 μL DNA template, 20 pmol of each primer and 6.4 μL PCR grade water. PCR was performed in a thermocycler (A & E, England) using the following conditions: 5 min at 95°C, followed by 30 cycles of 1 min s at 94°C, 1 min at 54°C for gdh gene, 1 min at 56°C for toxin genes, 1 min at 72°C, and a final extension of 10 min at 72°C. The presence of each gene was determined by electrophoresis on a 1.5% agarose gel. In each PCR run, DNA template from a toxigenic C. difficile and water were used as positive and negative controls, respectively.

RESULTS

From the 100 patients with diarrhea, 45 (45%) cases were males and 55 (55%) cases were females. The stool samples were obtained from ICU ward (62%), infectious ward (15%) and other wards including respiratory, hematology, neurology, gastroenterology and internal medicine (23%). From the 100 stool samples, eight (8%) samples were positive in C. difficile culture. In toxigenic culture, two (2%) of these strains, had cytopathic effects (CPE) on Vero cells (Fig. 1). Cytopathic effects of C. difficile toxins on spindle form Vero cells characterized by rounding up these cells. Demographic data of eight patients with positive C. difficile culture is shown in Table 2. A toxigenic C. difficile strain was isolated from a woman in infectious ward, and another toxigenic strain isolated from a man in ICU ward.
Fig. 1.

Cytopathic effects (CPE) of C. difficile supernatant on Vero cells. A; Toxin negative C. difficile B; Toxin positive C. difficile. CPE: Toxins deform Vero cells from spindle form to round form in more than 50% of the cells.

Table 2.

Demographic data of eight patients with positive C. difficile culture.

Male / FemaleAgeHospital wardLength of admission (days)Antibiotic usedToxigenic cultureGene
F23Infectious10Clindamycin Ceftriaxone+gdh, tcdB
M49ICU16Levofloxacin+gdh, tcdA, tcdB
F72ICU8Ceftriaxone-gdh
F80ICU44Ciprofloxacin- Cefepime-gdh
F77ICU20Meropenem- Ciprofloxacin-gdh
F79ICU10Meropenem-Vancomycin- Ciprofloxacin-gdh
F35ICU12Meropenem-Levofloxacin-Nitromicin Amphotericin-Fluconazole-Cotrimoxazole-gdh
M80ICU47Cefepime-Colistin-Levofloxacin Erythromycin-Fluconazole-gdh
Cytopathic effects (CPE) of C. difficile supernatant on Vero cells. A; Toxin negative C. difficile B; Toxin positive C. difficile. CPE: Toxins deform Vero cells from spindle form to round form in more than 50% of the cells. Demographic data of eight patients with positive C. difficile culture. All eight strains had the gdh gene (Fig. 2). This gene is specific for C. difficile (2). Among these eight strains, two strains that previously had cytopathic effects on toxigenic culture were positive for toxin genes. The strain isolated from the feces of the 49-year-old man was positive for tcdA and tcdB genes, and the strain isolated from the feces of a 23-year-old female patient was positive for the tcdB gene only (Fig. 3, Table 2).
Fig. 2.

PCR products of the gdh gene. M: DNA size marker, 100 base pair, Lanes1, 2, and 3: PCR products of the gdh gene (736 bp) for three C. difficile strains. P: Positive control sample, N: Negative control sample.

Fig. 3.

PCR products of tcdB and tcdA genes. M: DNA size marker, 100 base pair, Lane1: PCR product of tcdB gene (410 bp), 2: PCR product of tcdA gene (629 bp), Pa: positive control for tcdB gene, Pb: positive control for tcdA gene. N: Negative control sample.

PCR products of the gdh gene. M: DNA size marker, 100 base pair, Lanes1, 2, and 3: PCR products of the gdh gene (736 bp) for three C. difficile strains. P: Positive control sample, N: Negative control sample. PCR products of tcdB and tcdA genes. M: DNA size marker, 100 base pair, Lane1: PCR product of tcdB gene (410 bp), 2: PCR product of tcdA gene (629 bp), Pa: positive control for tcdB gene, Pb: positive control for tcdA gene. N: Negative control sample.

DISCUSSION

Infections with C. difficile have significantly increased over the past two decades (17). Infections with this organism have been reported from Australia (5), European countries (18) and the United States (19). C. difficile infections usually occur after treatment with antibiotics in hospitalized patients. Antibiotics such as β-lactams and clindamycin decrease the normal flora of the intestine and ultimately create the condition for further growth of C. difficile in the intestine as well as the development of clinical symptoms associated with this infection (20, 21). The pathogenicity of this bacterium is related to two major virulence factors of enterotoxin A and cytotoxin B (22, 23). Strains that have the ability to only produce toxin B are clinically important (24, 25). This study for the first time examined the frequency of toxigenic C. difficile strains in hospitalized patients in Babol hospitals. The frequency of toxin positive C. difficile among diarrheal patients by toxigenic culture and PCR was 2%. In 2016, Lotfian et al. studied 171 samples of suspected cases of diarrhea associated with C. difficile in Tehran. Their results showed that 10 (5.8%) samples were positive with both PCR and toxigenic culture. Of these 10 strains, 8 strains were tcdA + B + and 2 strains were tcdA–B +. They found very good agreement between toxigenic culture and PCR. Our study, similar to Lotfian et al., showed that PCR has good agreement with the toxigenic culture method (26). Another study by Sadeghifard et al. in 2004 was carried out on stool specimens from patients with diarrhea in Tehran hospitals. In their report, the prevalence of toxin producing C. difficile by the cytotoxicity method was 6.1% (27). Azizi et al., in 2011, studied 98 diarrheal patients in Tehran and reported 39.8% (39) samples as C. difficile culture-positive. Among 39 C. difficile strains, 15 (15.3%) strains were positive for toxin genes, 12 (12.2%) strains had toxin B and A, two (2%) strains had only toxin A (A+B−) and one (1%) strains had only toxin B (A–B+) (28). In another study in Iran, conducted by Goodarzi et al. in 2012, 108 patients with diarrhea were studied at Taleghani Hospital in Tehran. From 108 patients, 17 (15.7%) toxigenic strains were isolated. Among the 17 strains, four (23.9%) strains had only toxin B (AB+), one (5.9%) strain had only toxin A (A+B−), and 12 (70%) strains had both toxins (A+B+) (29). In the present study, frequency of toxigenic strains of C. difficile isolated from the patients with diarrhea in Babol was low (2%). In the study by Sadeghifard et al. and Lotfian et al., similar to the present study, the prevalence of toxigenic strains of C. difficile was reported low (6.1% and 5.8%, respectively) (30). Prevalence of diarrhea in a Turkish hospital was reported 7% of all hospital infections and C. difficile was isolated from 18.2% of hospitalized patients with diarrhea (31). In a study by Garcia et al., which was conducted in Brazil, prevalence of toxigenic strains of C. difficile in diarrheal patients was reported at 13.8% (32). Sachu et al., in 2018, studied 660 patients with AAD in India, and they identified C. difficile infection in 9.7% patients by NAAT (33). The prevalence of toxigenic strains of C. difficile in other countries like India (34), Indonesia (35), and Germany (36) were reported as 4%, 5.6%, and 11.1%, respectively. Due to geographical changes, diarrhea accounts for 1–14% of all hospital infections worldwide (30). Prevalence of C. difficile diarrhea differ according to the population of different hospitals and is affected by predisposing factors such as age, type and duration of antibiotic use, severity of underlying diseases and duration of admission (37, 38). In this study, for the first time C. difficile infection was identified in patients with diarrhea in Babol hospitals. PCR assay had good correlation with toxigenic culture, therefore, it can replace the laborious and costly cell culture method.
  32 in total

1.  The diagnosis and treatment of Clostridium difficile in antibiotic-associated diarrhea.

Authors:  L Gorenek; U Dizer; B Besirbellioglu; C P Eyigun; A Hacibektasoglu; D H Van Thiel
Journal:  Hepatogastroenterology       Date:  1999 Jan-Feb

2.  In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada.

Authors:  Anne-Marie Bourgault; François Lamothe; Vivian G Loo; Louise Poirier
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

3.  Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease.

Authors:  S P Sambol; M M Merrigan; D Lyerly; D N Gerding; S Johnson
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Binary toxin producing Clostridium difficile strains.

Authors:  M Rupnik; M Grabnar; B Geric
Journal:  Anaerobe       Date:  2003-12       Impact factor: 3.331

Review 5.  Emergence of Clostridium difficile-associated disease in North America and Europe.

Authors:  E J Kuijper; B Coignard; P Tüll
Journal:  Clin Microbiol Infect       Date:  2006-10       Impact factor: 8.067

6.  Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile.

Authors:  Ludovic Lemee; Anne Dhalluin; Sabrina Testelin; Marie-Andre Mattrat; Karine Maillard; Jean-François Lemeland; Jean-Louis Pons
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

7.  Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital.

Authors:  Barbara Geric; Maja Rupnik; Dale N Gerding; Miklavz Grabnar; Stuart Johnson
Journal:  J Med Microbiol       Date:  2004-09       Impact factor: 2.472

8.  Characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping.

Authors:  Renate J van den Berg; Eric C J Claas; Duddy H Oyib; Corné H W Klaassen; Lenie Dijkshoorn; Jon S Brazier; Ed J Kuijper
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

9.  Estimation of faecal carriage of Clostridium difficile in patients with ulcerative colitis using real time polymerase chain reaction.

Authors:  Ramadass Balamurugan; V Balaji; Balakrishnan S Ramakrishna
Journal:  Indian J Med Res       Date:  2008-05       Impact factor: 2.375

10.  Multicenter evaluation of a new screening test that detects Clostridium difficile in fecal specimens.

Authors:  L Zheng; S F Keller; D M Lyerly; R J Carman; C W Genheimer; C A Gleaves; S J Kohlhepp; S Young; S Perez; K Ye
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

View more
  4 in total

1.  Clinical and microbial characterization of toxigenic Clostridium difficile isolated from antibiotic associated diarrhea in Egypt.

Authors:  Sherein G Elgendy; Sherine A Aly; Rawhia Fathy; Enas A E Deaf; Naglaa H Abu Faddan; Muhamad R Abdel Hameed
Journal:  Iran J Microbiol       Date:  2020-08

2.  Origin, genomic diversity and microevolution of the Clostridium difficile B1/NAP1/RT027/ST01 strain in Costa Rica, Chile, Honduras and Mexico.

Authors:  Enzo Guerrero-Araya; Claudio Meneses; Eduardo Castro-Nallar; Ana M Guzmán D; Manuel Álvarez-Lobos; Carlos Quesada-Gómez; Daniel Paredes-Sabja; César Rodríguez
Journal:  Microb Genom       Date:  2020-03-16

Review 3.  Imaging Inflammation and Infection in the Gastrointestinal Tract.

Authors:  Alex N Frickenstein; Meredith A Jones; Bahareh Behkam; Lacey R McNally
Journal:  Int J Mol Sci       Date:  2019-12-30       Impact factor: 5.923

4.  A worldwide systematic review and meta-analysis of bacteria related to antibiotic-associated diarrhea in hospitalized patients.

Authors:  Hamid Motamedi; Matin Fathollahi; Ramin Abiri; Sepide Kadivarian; Mosayeb Rostamian; Amirhooshang Alvandi
Journal:  PLoS One       Date:  2021-12-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.